• Something wrong with this record ?

Methylene Blue in the Treatment of Neuropsychiatric Disorders

M. Alda,

. 2019 ; 33 (8) : 719-725. [pub] -

Language English Country New Zealand

Document type Journal Article, Research Support, Non-U.S. Gov't, Review

E-resources Online Full text

NLK ProQuest Central from 2008-01-01 to 1 year ago
Health & Medicine (ProQuest) from 2008-01-01 to 1 year ago
Psychology Database (ProQuest) from 2008-01-01 to 1 year ago

Methylene blue is a long-established drug with complex pharmacology and multiple clinical indications. Its diverse mechanisms of action are most likely responsible for the large variety of its clinical effects. Of interest to psychiatrists, methylene blue has antidepressant, anxiolytic, and neuroprotective properties documented by both animal and human studies. Its stabilizing effect on mitochondrial function and dose-dependent effect on the generation of reactive oxygen species are of significant heuristic value. For these reasons, methylene blue holds promise as a proof-of-concept treatment of organic/neurodegenerative disorders and as a neuroprotective agent in general. In psychiatry, methylene blue has been used for over a century. It was tried successfully in the treatment of psychotic and mood disorders and as a memory enhancer in fear-extinction training. Particularly promising results have been obtained in both short- and long-term treatment of bipolar disorder. In these studies, methylene blue produced an antidepressant and anxiolytic effect without risk of a switch into mania. Long-term use of methylene blue in bipolar disorder led to a better stabilization and a reduction in residual symptoms of the illness. It is usually well tolerated, but caution is needed in the light of its inhibitory effect on monoamine oxidase A.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025733
003      
CZ-PrNML
005      
20201222160345.0
007      
ta
008      
201125s2019 nz f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s40263-019-00641-3 $2 doi
035    __
$a (PubMed)31144270
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a nz
100    1_
$a Alda, Martin $u Department of Psychiatry, Dalhousie University, 5909 Veterans' Memorial Lane, Halifax, NS, B3H 2E2, Canada. malda@dal.ca. National Institute of Mental Health, Klecany, Czech Republic. malda@dal.ca.
245    10
$a Methylene Blue in the Treatment of Neuropsychiatric Disorders / $c M. Alda,
520    9_
$a Methylene blue is a long-established drug with complex pharmacology and multiple clinical indications. Its diverse mechanisms of action are most likely responsible for the large variety of its clinical effects. Of interest to psychiatrists, methylene blue has antidepressant, anxiolytic, and neuroprotective properties documented by both animal and human studies. Its stabilizing effect on mitochondrial function and dose-dependent effect on the generation of reactive oxygen species are of significant heuristic value. For these reasons, methylene blue holds promise as a proof-of-concept treatment of organic/neurodegenerative disorders and as a neuroprotective agent in general. In psychiatry, methylene blue has been used for over a century. It was tried successfully in the treatment of psychotic and mood disorders and as a memory enhancer in fear-extinction training. Particularly promising results have been obtained in both short- and long-term treatment of bipolar disorder. In these studies, methylene blue produced an antidepressant and anxiolytic effect without risk of a switch into mania. Long-term use of methylene blue in bipolar disorder led to a better stabilization and a reduction in residual symptoms of the illness. It is usually well tolerated, but caution is needed in the light of its inhibitory effect on monoamine oxidase A.
650    _2
$a zvířata $7 D000818
650    _2
$a antidepresiva $x terapeutické užití $7 D000928
650    _2
$a bipolární porucha $x farmakoterapie $7 D001714
650    _2
$a strach $x účinky léků $7 D005239
650    _2
$a lidé $7 D006801
650    _2
$a methylenová modř $x terapeutické užití $7 D008751
650    _2
$a neuroprotektivní látky $x terapeutické užití $7 D018696
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
773    0_
$w MED00001186 $t CNS drugs $x 1179-1934 $g Roč. 33, č. 8 (2019), s. 719-725
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31144270 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222160341 $b ABA008
999    __
$a ok $b bmc $g 1599878 $s 1116419
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 33 $c 8 $d 719-725 $e - $i 1179-1934 $m CNS drugs $n CNS Drugs $x MED00001186
LZP    __
$a Pubmed-20201125

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...